Filing Details
- Accession Number:
- 0001104659-22-098245
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-09-07 16:54:49
- Reporting Period:
- 2022-09-02
- Accepted Time:
- 2022-09-07 16:54:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1763950 | Lantern Pharma Inc. | LTRN | Pharmaceutical Preparations (2834) | 463973463 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1813270 | Cavu Management, Lp | 1751 River Run, Suite 400 Fort Worth TX 76107 | No | No | Yes | No | |
| 1813310 | Cavu Advisors, Llc | 1751 River Run, Suite 400 Fort Worth TX 76107 | No | No | Yes | No | |
| 1813311 | Bp Directors, Lp | 1751 River Run, Suite 400 Fort Worth TX 76107 | No | No | Yes | No | |
| 1813316 | W. Leslie Kreis | C/O Lantern Pharma Inc. 1920 Mckinney Avenue, 7Th Floor Dallas TX 75201 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2022-09-02 | 26,100 | $1.03 | 26,100 | No | 4 | X | Indirect | By BP Directors,LP |
| Common Stock | Disposition | 2022-09-02 | 5,170 | $5.20 | 20,930 | No | 4 | S | Indirect | By BP Directors,LP |
| Common Stock | Acquisiton | 2022-09-02 | 6,438 | $1.03 | 27,328 | No | 4 | X | Indirect | By BP Directors,LP |
| Common Stock | Disposition | 2022-09-02 | 1,275 | $5.20 | 26,093 | No | 4 | S | Indirect | By BP Directors,LP |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | X | Indirect | By BP Directors,LP |
| No | 4 | S | Indirect | By BP Directors,LP |
| No | 4 | X | Indirect | By BP Directors,LP |
| No | 4 | S | Indirect | By BP Directors,LP |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option | Acquisiton | 2022-09-02 | 26,100 | $0.00 | 26,100 | $1.03 |
| Common Stock | Stock Option | Acquisiton | 2022-09-02 | 6,438 | $0.00 | 6,438 | $1.03 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 6,438 | 2018-12-17 | 2028-12-16 | No | 4 | X | Indirect |
| 0 | 2018-12-17 | 2028-12-16 | No | 4 | X | Indirect |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 564,038 | Indirect | By Bios Fund I, LP |
| Common Stock | 329,904 | Indirect | By Bios Fund I QP, LP |
| Common Stock | 204,723 | Indirect | By Bios Fund II, LP |
| Common Stock | 668,738 | Indirect | By Bios Fund II QP, LP |
| Common Stock | 89,522 | Indirect | By Bios Fund II NT, LP |
Footnotes
- On September 2, 2022, the reporting person exercised an option to purchase 26,100 shares of LTRN common stock for $1.03 a share. The reporting person paid the exercise price on a cashless basis, resulting in LTRN's withholding of 5,170 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 20,930 shares.
- On September 2, 2022, the reporting person exercised an option to purchase 6,438 shares of LTRN common stock for $1.03 a share. The reporting person paid the exercise price on a cashless basis, resulting in LTRN's withholding of 1,275 of the warrant shares to pay the exercise price and issuing to the reporting person the remaining 5,163 shares.
- Bios Equity Partners, LP ("Bios Equity I") is the general partner of the following entities: Bios Fund I, Bios Fund I QP and BP Directors, LP ("Bios Directors"). Bios Equity Partners II, LP ("Bios Equity II") is the general partner of the following entities: Bios Fund II, Bios Fund II QP and Bios Fund II NT. Cavu Management, LP ("Cavu Management"), an entity managed and controlled by Mr. Kreis, and Bios Capital Management, LP ("Bios Management"), an entity managed and controlled by Aaron Glenn Louis Fletcher, are each a general partner of Bios Equity I and Bios Equity II. Cavu Advisors LLC ("Cavu Advisors"), an entity that is managed and controlled by Mr. Kreis, is the general partner of Cavu Management. Bios Advisors GP, LLC ("Bios Advisors"), an entity that is managed and controlled by Mr. Fletcher, is the general partner of Bios Management.
- Mr. Kreis, Cavu Management, Cavu Advisors, Mr. Fletcher, Bios Management and Bios Advisors each share voting and investment control with respect to the shares held by Bios Fund I, Bios Fund I QP, Bios Directors, Bios Fund II, Bios Fund II QP and Bios Fund II NT (collectively, the "Bios Equity Entities"). Because of the relationship between Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors, Bios Advisors and the Bios Equity Entities, Mr. Kreis, Mr. Fletcher, Cavu Management, Bios Management, Cavu Advisors and Bios Advisors each may be deemed to beneficially own the shares held directly by the Bios Equity Entities.
- For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each Reporting Person disclaims beneficial ownership of any such securities, except to the extent of his/its pecuniary interest therein, if any, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of such securities for purposes of Section 16 or otherwise.
Billionaire Hedge Funds
